Methods and compositions for the treatment and prevention of smooth muscle cell proliferation
(19)AUSTRALIAN PATENT OFFICE (54) Title Methods and compositions for the treatment and prevention of smooth muscle cell proliferation (51)6 International Patent Classification(s) G01N 033/567 A61K 038/16 C07K 016/00 A61K 038/24 C07H 021/04 C07K 017/00 C07K 001/00 A61K 039/395 A61K 038/00 C07K 014/00 (21) Application No: 2002335493 (22) Application Date: 2002 .03.04 (87) WIPO No: WO02/069899 (30) Priority Data (31) Number (32) Date 60/272,951 2001 .03.02 (33) Country US 200510067 (43) Publication Date : 2002.09.19 (43) Publication Journal Date : 2003 .03.13 (71) Applicant(s) Reddy US Therapeutics, Inc. (72) Inventor(s) Pillarisetti, Sivaram(-1-1) Application NoAU2002335493 A8(19)AUSTRALIAN PATENT OFFICE (54) Title Methods and compositions for the treatment and prevention of smooth muscle cell proliferation (51)6 International Patent Classification(s) G01N 033/567 A61K 038/16 C07K 016/00 A61K 038/24 C07H 021/04 C07K 017/00 C07K 001/00 A61K 039/395 A61K 038/00 C07K 014/00 (21) Application No: 2002335493 (22) Application Date: 2002 .03.04 (87) WIPO No: WO02/069899 (30) Priority Data (31) Number (32) Date 60/272,951 2001 .03.02 (33) Country US 200510067 (43) Publication Date : 2002.09.19 (43) Publication Journal Date : 2003 .03.13 (71) Applicant(s) Reddy US Therapeutics, Inc. (72) Inventor(s) Pillarisetti, Sivaram-1- Methods and Compositions for the Treatment and Prevention of Smooth Muscle Cell Proliferation The present invention is directed to methods and compositions for diagnosing, treating and preventing smooth muscle cell proliferation and hyperplasia, including vascular occlusive conditions. Such conditions include, but are not limited to, thrombosis, atherosclerosis and restenosis after angioplasty. Preferred embodiments comprise methods and compositions that effect HSPGs associated with smooth muscle cell proliferation and more preferably, effect perlecan. ClaimsWhat is claimed is:1. A method for detecting compounds that effect cell proliferation, comprising, a) adding to cells a composition comprising a compound suspected of effecting cell proliferation; b) measuring cell proliferation; and c) comparing cell proliferation in b) to cell proliferation in cells not treated with the compound.
2. The method of Claim 1, wherein cell proliferation is determined by measuring the amount of HSPG.
3. The method of Claim 3, wherein the HSPG is perlecan, syndecan or glypican.
4. The method of Claim 2, wherein the HSPG is perlecan.
5. The method of Claim 1, wherein the compound is a chemical element, molecule, compound, mixture, emulsion, chemotherapeutic agent, pharmacological agent, hormone, antibody, growth factor, cellular factor, nucleic acid, protein, peptide, peptidomimetic, nucleotide, carbohydrate, and combinations, fragments, analogs or derivatives of such entities.
6. A composition, comprising, a compound capable of effecting cellular proliferation.
7. The composition of Claim 6, wherein the compound increases HSPG production.
8. The composition of Claim 6, wherein the compound decreases the production of HSPG.
9. The composition of Claim 6, wherein the compound is a chemical element, molecule, compound, mixture, emulsion, chemotherapeutic agent, pharmacological agent, hormone, antibody, growth factor, cellular factor, nucleic acid, protein, peptide, peptidomimetic, nucleotide, carbohydrate, and combinations, fragments, analogs or derivatives of such entities.
10. The composition of Claim 6, wherein the compound increases cell proliferation as determined by the method of Claim 1.
11. The composition of Claim 6, wherein the compound decreases cell proliferation as determined by the method of Claim 1.
12. The composition of Claim 6, wherein the composition comprises a nucleic acid vector.
13. The composition of Claim 6, further comprising a pharmaceutically acceptable carrier.
14. A method for treating vascular occlusive conditions, comprising, administering a composition comprising one or more compounds in an effective amount for inducing HSPG synthesis.
15. The method of Claim 14 wherein the HSPG is syndecan, glypican or perlecan.
16. The method of Claim 14 wherein the vascular occlusive condition is atherosclerosis, thrombosis, transplant vasculopathy, cardiac allograft vasculopathy or restenosis.